NO20020130L - Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis - Google Patents

Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis

Info

Publication number
NO20020130L
NO20020130L NO20020130A NO20020130A NO20020130L NO 20020130 L NO20020130 L NO 20020130L NO 20020130 A NO20020130 A NO 20020130A NO 20020130 A NO20020130 A NO 20020130A NO 20020130 L NO20020130 L NO 20020130L
Authority
NO
Norway
Prior art keywords
cell migration
fviia
chemotaxis
gene expression
tissue factor
Prior art date
Application number
NO20020130A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020130D0 (no
Inventor
Mirella Ezban
Lars Christian Petersen
Agneta Siegbahn
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20020130D0 publication Critical patent/NO20020130D0/no
Publication of NO20020130L publication Critical patent/NO20020130L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO20020130A 1999-07-14 2002-01-11 Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis NO20020130L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199901023 1999-07-14
US14830099P 1999-08-11 1999-08-11
DKPA199901117 1999-08-12
PCT/DK2000/000401 WO2001005353A2 (en) 1999-07-14 2000-07-14 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS

Publications (2)

Publication Number Publication Date
NO20020130D0 NO20020130D0 (no) 2002-01-11
NO20020130L true NO20020130L (no) 2002-03-13

Family

ID=27221063

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020130A NO20020130L (no) 1999-07-14 2002-01-11 Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis

Country Status (19)

Country Link
US (3) US20020193302A1 (ja)
EP (1) EP1200116B1 (ja)
JP (1) JP2003525028A (ja)
KR (1) KR100821644B1 (ja)
CN (1) CN100411684C (ja)
AT (1) ATE411041T1 (ja)
AU (1) AU5807500A (ja)
BR (1) BR0012408A (ja)
CA (1) CA2378249A1 (ja)
CZ (1) CZ200240A3 (ja)
DE (1) DE60040539D1 (ja)
ES (1) ES2316372T3 (ja)
HU (1) HUP0302052A3 (ja)
IL (1) IL147294A0 (ja)
MX (1) MXPA02000468A (ja)
NO (1) NO20020130L (ja)
PL (1) PL353035A1 (ja)
RU (1) RU2268744C2 (ja)
WO (1) WO2001005353A2 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098359A2 (en) * 2000-06-21 2001-12-27 Wyeth Cyr61 as a target for treatment and diagnosis of breast cancer
DE10238429A1 (de) 2002-03-19 2003-10-30 Aventis Behring Gmbh Intellect Marburg I Mutante der Faktor VII aktivierenden Protease (FSAP) als Risikofaktor für Atherosklerose
AU2002336920A1 (en) * 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
AU2003214920A1 (en) * 2002-02-04 2003-09-02 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
AU2004284013A1 (en) * 2003-08-06 2005-05-06 Sirnasense As The use of siRNA silencing in the prevention of metastasis
MXPA06011952A (es) * 2004-04-16 2007-01-16 Scripps Research Inst Metodo para modulacion de vascularizacion.
EP1945261A4 (en) * 2005-11-07 2010-05-12 Scripps Research Inst COMPOSITIONS AND METHODS FOR CONTROLLING THE SPECIFICITY OF TISSUE FACTOR SIGNALING
US20100015160A1 (en) * 2007-02-21 2010-01-21 Yale University Compositions and methods for diagnosing and treating endometriosis
US10391137B2 (en) 2011-07-01 2019-08-27 Shiseido Company, Ltd. Platelet-derived growth factor-BB production promotor, and mesenchymal stem cell production accelerator, stem cell stabilizer and dermal regenerator comprising the same
CN109381478A (zh) * 2018-10-31 2019-02-26 青岛大学附属医院 一种miRNA在制备抑制新生血管生成和抑制VEGF-A因子表达的试剂中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT67693A (en) 1991-10-11 1995-04-28 Novo Nordisk As Hemostatic composition for arresting local bleedings
DE19538715A1 (de) * 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
US6413735B1 (en) 1996-03-15 2002-07-02 Munin Corporation Method of screening for a modulator of angiogenesis
AU7907398A (en) 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
ATE454161T1 (de) * 1997-07-18 2010-01-15 Novo Nordisk Healthcare Ag Verwendung von fviia oder fviiai zur behandlung von endothelialer fehlfunktion bzw zur inhibierung der angiogenese
US20030040481A1 (en) * 1997-07-18 2003-02-27 Lars Kongsbak Methods for modifying cell motility using a factor VIIa antagonist
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
PL371800A1 (en) 2001-03-22 2005-06-27 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
IL158615A0 (en) 2001-05-02 2004-05-12 Novo Nordisk As Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome
PL369077A1 (en) 2001-07-20 2005-04-18 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides
WO2003039581A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
JP2006510568A (ja) 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
EP1446155A1 (en) 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmaceutical composition comprising factor vii polypeptides and aprotinin polypeptides
BR0213953A (pt) 2001-11-09 2004-08-31 Novo Nordisk Healthcare Ag Composição farmacêutica, kit de partes, uso de fator vii ou um polipeptìdeo relacionado com fator vii em combinação com um fator v ou um polipeptìdeo relacionado com fator v, uso de uma composição, métodos para tratar episódios de sangramento em um sujeito, para reduzir o tempo de coagulação, para intensificar hemóstase, para prolongar o tempo de lise de coágulos em um sujeito, e para incrementar a resistência do coágulo em um sujeito, kit contendo um tratamento para episódios de sangramento

Also Published As

Publication number Publication date
CN1460024A (zh) 2003-12-03
EP1200116A2 (en) 2002-05-02
NO20020130D0 (no) 2002-01-11
CN100411684C (zh) 2008-08-20
DE60040539D1 (de) 2008-11-27
JP2003525028A (ja) 2003-08-26
BR0012408A (pt) 2002-03-12
CZ200240A3 (cs) 2003-04-16
WO2001005353A3 (en) 2001-07-19
ATE411041T1 (de) 2008-10-15
RU2268744C2 (ru) 2006-01-27
MXPA02000468A (es) 2008-10-06
PL353035A1 (en) 2003-10-06
US20020193302A1 (en) 2002-12-19
CA2378249A1 (en) 2001-01-25
US20050239708A1 (en) 2005-10-27
IL147294A0 (en) 2002-08-14
EP1200116B1 (en) 2008-10-15
KR100821644B1 (ko) 2008-04-11
HUP0302052A2 (hu) 2003-09-29
ES2316372T3 (es) 2009-04-16
KR20020025194A (ko) 2002-04-03
US20090036378A1 (en) 2009-02-05
AU5807500A (en) 2001-02-05
WO2001005353A2 (en) 2001-01-25
HUP0302052A3 (en) 2005-12-28
US7829529B2 (en) 2010-11-09

Similar Documents

Publication Publication Date Title
DE50310980D1 (de) VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE
NO20020130L (no) Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis
NO961888L (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
DE69931055D1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
NO20071019L (no) Quinazolinderivater og deres anvendelse ved behandling av trombocytemi
MX2009004051A (es) Uso de antagonistas de il-1 para tratar gota y pseudo gota.
ATE452185T1 (de) Dimethylarginin-dimethylaminohydrolasen
ATE275919T1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
DE60019318D1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
NO992187L (no) Isolert tumornekrosefaktor-reseptor utl°sende enzym, sammensetninger som omfatter enzymet og metoder for bruken derav
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
BR0315344A (pt) Métodos para prever edema como um efeito colateral do tratamento com drogas
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE69329802D1 (de) Syndecan-stimulierung der zellulären differenzierung
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
NO20010390L (no) Behandling av angstsykdommer
DE50308460D1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
WO2003037361A3 (en) Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
DE60304451D1 (de) Verwendung von ceramiden in haarbehandlungsmitteln